Humira's approval widened to include ulcerative colitis

October 1, 2012
Humira's approval widened to include ulcerative colitis

(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

Humira—an anti- agent that's designed to suppress abnormal inflammatory and immune responses—has already been approved to treat a host of conditions, including , Crohn's disease, and plaque psoriasis.

Ulcerative colitis affects about 620,000 people in the United States, according to the U.S. National Institutes of Health.

The most common side effects of Humira include infection, injection-site reaction, headache, and rash, according to an FDA news release.

The drug is manufactured by Abbott Laboratories, based in North Chicago, Ill.

Explore further: Test approved to help treat common infection in transplant patients

More information: The U.S. National Library of Medicine has more about ulcerative colitis.


Related Stories

Marqibo approved for ph- acute lymphoblastic leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL).

Marqibo approved for rare leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.